



Wainzua in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

NEUROLOGY · HEREDITARY ATTR AMYLOIDOSIS

The clinical situation

Wainzua (eplontersen) is an FDA-approved ligand-conjugated antisense oligonucleotide targeting hepatic TTR mRNA, indicated for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), dosed 45 mg SC monthly. Manufactured by AstraZeneca / Ionis. Refrigerated shipment is required; vitamin A supplementation recommended during treatment; self-administration possible after training.

The pathway, 5 steps

- 1 Consultation & genetic confirmation.** Treating neurologist confirms TTR variant and hATTR-PN phenotype; baseline neurologic and cardiac assessment documented.
- 2 Treating centre & prescription confirmed.** A Saudi tertiary centre (Riyadh or Jeddah) issues the prescription and commits to monthly SC administration training.
- 3 SFDA named-patient application.** Clinical rationale, genetic report, prescription, and product details are filed with SFDA for named-patient import clearance.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked to monthly schedule.
- 5 Administration & monitoring.** Monthly SC injection (training-supported self-administration possible); vitamin A supplementation, neurologic, and cardiac monitoring per label.

Indicative economics

Reference US cash-pay range: USD 40,000–50,000 per monthly dose drug-only. Cold-chain logistics, SFDA documentation, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** SFDA named-patient package with genetic confirmation. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Wainzua × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/wainzua-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team